This is the first time that a study has highlighted the significance of BRD4/PI3K/PTEN/AKT inhibition in surpassing imatinib resistance in GIST, thus indicating that targeting BRD4 may be a promising strategy to improve therapy in GISTs with acquired or de novo imatinib resistance. Here, BRD4 is linked to gastrointestinal stromal tumor.